Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway Glioma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Visual Pathway Glioma
Conditions
Brief summary
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of entinostat administered as a single-agent, once weekly to children with recurrent or refractory solid tumors. II. To define and describe the toxicities of entinostat administered as a single agent, once weekly to children with recurrent or refractory solid tumors. III. To characterize the pharmacokinetics of entinostat in children with recurrent or refractory cancer. SECONDARY OBJECTIVES: I. To preliminarily define the antitumor activity of entinostat within the confines of a phase 1 study. II. To assess change in histone H3 and H4 acetylation in peripheral blood mononuclear cells (PBMCs) as a marker of the biologic activity of entinostat. OUTLINE: This is a dose escalation study. Patients receive entinostat orally (PO) on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
Interventions
DRUGEntinostat
Given PO
OTHERLaboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to 21 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have a body surface area (BSA) of \>= 1.17 m\^2 at time of study enrollment * Patients must be able to swallow intact tablets * Patients with recurrent or refractory solid tumors, including central nervous system (CNS) tumors or lymphoma, are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG) * Patients must have either measurable or evaluable disease * Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately * Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment * Solid tumor patients: \>= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea) * Lymphoma patients: * a waiting period prior to enrollment is not required for patients receiving standard cytotoxic maintenance chemotherapy (i.e. corticosteroid, vincristine, thioguanine\[6MP\], and/or methotrexate) * \>=14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy; additionally, patients must have fully recovered from all acute toxic effects of prior therapy; Note: cytoreduction with hydroxyurea must be discontinued \>= 24 hours prior to the start of protocol therapy * Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count \[ANC\] counts): \>= 7 days must have elapsed from the last dose of agent; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment * Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1 * Hematopoietic growth factors: \>= 14 days must have elapsed from the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator * Interleukins, interferons and cytokines (other than hematopoietic growth factors): \>= 21 days must have elapsed from the last dose of interleukins, interferon or cytokines (other than hematopoietic growth factors) * Stem cell infusions (with or without traumatic brain injury \[TBI\]): * Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: \>= 84 days must have elapsed from infusion and no evidence of graft versus host disease (GVHD) * Autologous stem cell infusion including boost infusion: \>= 42 days must have elapsed from infusion * Cellular therapy: \>= 42 days must have elapsed from last dose of any type of cellular therapy (e.g. modified T cells, natural killer \[NK\] cells, dendritic cells, etc.) * External beam radiation (XRT)/external beam irradiation including protons: \>= 14 days must have elapsed after local XRT; \>= 150 days after TBI, craniospinal XRT or if radiation to 50% of the pelvis; \>= 42 days if other substantial bone marrow (BM) radiation * Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131 \[131I-MIBG\]): \>= 42 days must have elapsed from the last dose of systemically administered radiopharmaceutical therapy * Histone deacetylase (HDAC) inhibitors: Patients must not have received prior therapy with entinostat; patients who have received therapy with other HDAC inhibitors are eligible * Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3 (within 7 days prior to enrollment) * Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (within 7 days prior to enrollment) * Hemoglobin \>= 8.0 g/dl, with or without transfusion (within 7 days prior to enrollment) * Patients with known bone marrow metastatic disease will not be eligible * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * 1 to \< 2 years: 0.6 mg/dL for males and females * 2 to \< 6 years: 0.8 mg/dL for males and females * 6 to \< 10 years: 1.0 mg/dL for males and females * 10 to \< 13 years: 1.2 mg/dL for males and females * 13 to \< 16 years: 1.5 mg/dL for males and 1.4 mg/dL for females * \> = 16 years: 1.7 mg/dL for males and 1.4 mg/dL for females (within 7 days prior to enrollment) * Bilirubin (sum of conjugated + conjugated) =\< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x upper limit of normal (ULN) = 135 U/l; for the purpose of this study, the ULN for SGPT is 45 U/l (within 7 days prior to enrollment) * Serum albumin \>= 2 g/dl (within 7 days prior to enrollment) * All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion criteria
* Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 3 months after participation in this study; abstinence is an acceptable method of contraception; those who become pregnant while on treatment with entinostat must discontinue immediately and consult their treating physician * Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents are not eligible * Patients requiring concurrent administration of valproic acid are not eligible for this trial * Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial * Patients with a BSA ˂ 1.17 m\^2 at time of study enrollment are not eligible * Patients who are not able to swallow intact tablets are not eligible * Patients with a known history of corrected QT (QTc) prolongation (\> 480 msec), or known history of ventricular tachycardia, ventricular fibrillation or Torsades de pointes are not eligible * Patients who have an uncontrolled infection are not eligible * Patients who have received a prior solid organ transplantation are not eligible * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible * Patients with a history of allergy to medications that have a benzamide structure (e.g., metoclopramide, procarbazine, domperidone, cisapride etc.) are not eligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | Up to 96 hours | The median (min, max) of the time to reach maximum plasma concentration of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1. |
| Half-life of Entinostat | Plasma concentrations were measured at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1. | The median (min, max) Half-Life of entinostat stratified by study part and dose level. The half-life (t1/2) was calculated using the equation t1/2 = 0.693/λz, where the terminal elimination rate constant (λz) was determined from a least-squares regression of the log-transformed plasma concentration vs. time data for the last 3 - 4 time points. |
| Peak Plasma Concentration of Entinostat: C-Max | Up to 96 hours | The median (min, max) of the peak plasma concentration of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1. |
| Total Area Under the Plasma Concentration Curve of Entinostat: AUC | Up to 96 hours | The median (min, max) of the total area under the plasma concentration curve of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1. |
| Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat | Up to 28 days | The MTD/RP2D will be defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy among 6 toxicity-evaluable patients. The frequency of cycle 1 dose limiting toxicities will be summarized by dose level among patients in the dose escalation part of the study. |
| Frequency of Adverse Events for Entinostat | Up to 28 days | The frequency of patients with at least one Grade 3 or greater adverse event that are at least possibly attributable to entinostat during cycle 1 will be summarized by study part, dose level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Histone H3 Acetylation of Entinostat | Up to 28 days | Median (IQR) change in H3 acetylation in peripheral blood mononuclear cells (PBMCs) versus baseline stratified by study part, dose level. |
| Change in Histone H4 Acetylation of Entinostat | Up to 28 days | Median (IQR) change in H4 acetylation in PBMCs versus baseline stratified by study part, dose level. |
| Antitumor Activity of Entinostat | Up to 4 years 9 months | Frequency of response to entinostat per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and/or assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, stratified by study part and dose |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Stratum 1 With 3 mg/m² Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 3 mg/m2 | 6 |
| Stratum 1 With 4 mg/m² Patients with recurrent or refractory solid tumors, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at 4 mg/m2 | 9 |
| PK Part With 4 mg/m² Patients with recurrent or refractory solid tumors without bone marrow involvement, including lymphoma and CSN tumors, treated once weekly with entinostat administered as a single-agent at the RP2D (4 mg/m2) | 6 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 0 |
| Overall Study | Lack of Efficacy | 5 | 8 | 4 |
| Overall Study | Physician Decision | 0 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Total | PK Part With 4 mg/m² | Stratum 1 With 3 mg/m² | Stratum 1 With 4 mg/m² |
|---|---|---|---|---|
| Age, Categorical <=18 years | 18 Participants | 5 Participants | 4 Participants | 9 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 1 Participants | 2 Participants | 0 Participants |
| Age, Continuous | 14 years | 11 years | 17.5 years | 13 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 1 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 16 Participants | 5 Participants | 5 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 15 Participants | 3 Participants | 6 Participants | 6 Participants |
| Sex: Female, Male Female | 11 Participants | 4 Participants | 2 Participants | 5 Participants |
| Sex: Female, Male Male | 10 Participants | 2 Participants | 4 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 6 | 0 / 9 | 2 / 6 |
| other Total, other adverse events | 6 / 6 | 9 / 9 | 6 / 6 |
| serious Total, serious adverse events | 5 / 6 | 7 / 9 | 5 / 6 |
Outcome results
Primary
Frequency of Adverse Events for Entinostat
The frequency of patients with at least one Grade 3 or greater adverse event that are at least possibly attributable to entinostat during cycle 1 will be summarized by study part, dose level.
Time frame: Up to 28 days
Population: All eligible enrolled patients.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Entinostat) | Frequency of Adverse Events for Entinostat | 5 Participants |
| Stratum 1 With 4 mg/m² | Frequency of Adverse Events for Entinostat | 7 Participants |
| PK Part With 4 mg/m² | Frequency of Adverse Events for Entinostat | 5 Participants |
Primary
Half-life of Entinostat
The median (min, max) Half-Life of entinostat stratified by study part and dose level. The half-life (t1/2) was calculated using the equation t1/2 = 0.693/λz, where the terminal elimination rate constant (λz) was determined from a least-squares regression of the log-transformed plasma concentration vs. time data for the last 3 - 4 time points.
Time frame: Plasma concentrations were measured at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.
Population: All eligible enrolled patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Entinostat) | Half-life of Entinostat | 50.96 Hours |
| Stratum 1 With 4 mg/m² | Half-life of Entinostat | 46.04 Hours |
| PK Part With 4 mg/m² | Half-life of Entinostat | 44.23 Hours |
Primary
Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat
The MTD/RP2D will be defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy among 6 toxicity-evaluable patients. The frequency of cycle 1 dose limiting toxicities will be summarized by dose level among patients in the dose escalation part of the study.
Time frame: Up to 28 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Entinostat) | Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat | 4 mg/m² |
Primary
Peak Plasma Concentration of Entinostat: C-Max
The median (min, max) of the peak plasma concentration of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.
Time frame: Up to 96 hours
Population: All eligible enrolled patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Entinostat) | Peak Plasma Concentration of Entinostat: C-Max | 54.4 ng/ml |
| Stratum 1 With 4 mg/m² | Peak Plasma Concentration of Entinostat: C-Max | 61.5 ng/ml |
| PK Part With 4 mg/m² | Peak Plasma Concentration of Entinostat: C-Max | 23.8 ng/ml |
Primary
Time to Reach Maximum Plasma Concentration of Entinostat: T-Max
The median (min, max) of the time to reach maximum plasma concentration of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.
Time frame: Up to 96 hours
Population: All eligible enrolled patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Entinostat) | Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | 1.01 Hours |
| Stratum 1 With 4 mg/m² | Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | 0.59 Hours |
| PK Part With 4 mg/m² | Time to Reach Maximum Plasma Concentration of Entinostat: T-Max | 1 Hours |
Primary
Total Area Under the Plasma Concentration Curve of Entinostat: AUC
The median (min, max) of the total area under the plasma concentration curve of entinostat stratified by study part, dose level. Time points were assessed at 0, 0.5, 1, 3, 6, 24, and 48-96 hours post-dose during cycle 1, day 1.
Time frame: Up to 96 hours
Population: All eligible enrolled patients.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Entinostat) | Total Area Under the Plasma Concentration Curve of Entinostat: AUC | 755 hr*ng/mL |
| Stratum 1 With 4 mg/m² | Total Area Under the Plasma Concentration Curve of Entinostat: AUC | 1111 hr*ng/mL |
| PK Part With 4 mg/m² | Total Area Under the Plasma Concentration Curve of Entinostat: AUC | 1147 hr*ng/mL |
Secondary
Antitumor Activity of Entinostat
Frequency of response to entinostat per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and/or assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, stratified by study part and dose
Time frame: Up to 4 years 9 months
Population: All eligible enrolled patients.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Entinostat) | Antitumor Activity of Entinostat | 0 Participants |
| Stratum 1 With 4 mg/m² | Antitumor Activity of Entinostat | 0 Participants |
| PK Part With 4 mg/m² | Antitumor Activity of Entinostat | 0 Participants |
Secondary
Change in Histone H3 Acetylation of Entinostat
Median (IQR) change in H3 acetylation in peripheral blood mononuclear cells (PBMCs) versus baseline stratified by study part, dose level.
Time frame: Up to 28 days
Population: Data were not collected
Secondary
Change in Histone H4 Acetylation of Entinostat
Median (IQR) change in H4 acetylation in PBMCs versus baseline stratified by study part, dose level.
Time frame: Up to 28 days
Population: Data were not collected